NexImmune, Inc.

Symbol: NEXI

NASDAQ

5.72

USD

Market price today

  • 0.0006

    P/E Ratio

  • -0.0000

    PEG Ratio

  • 6.77M

    MRK Cap

  • 0.00%

    DIV Yield

NexImmune, Inc. (NEXI) Financial Statements

On the chart you can see the default numbers in dynamics for NexImmune, Inc. (NEXI). Companys revenue shows the average of 0 M which is 0.000 % gowth. The average gross profit for the whole period is -0.57 M which is -0.090 %. The average gross profit ratio is 0.000 %. The net income growth for the company last year performance is -63.904 % which equals -9.124 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of NexImmune, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 198.582. In the realm of current assets, NEXI clocks in at 5400.959 in the reporting currency. A significant portion of these assets, precisely 3202.452, is held in cash and short-term investments. This segment shows a change of 91.443% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0 in the reporting currency. This figure signifies a year_over_year change of 66.143%. Shareholder value, as depicted by the total shareholder equity, is valued at 3509.717 in the reporting currency. The year over year change in this aspect is 107.658%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 0, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

balance-sheet.row.cash-and-short-term-investments

52.243202.534.681.8
5
10.1
12.1

balance-sheet.row.short-term-investments

1.440051.5
0
1
11.6

balance-sheet.row.net-receivables

0.1900.10
0
0
0.1

balance-sheet.row.inventory

4.54000
0
0.1
0

balance-sheet.row.other-current-assets

2.112198.52.70.1
0.1
0.8
0.2

balance-sheet.row.total-current-assets

59.63540137.486.3
8.4
11
12.3

balance-sheet.row.property-plant-equipment-net

15.381399.65.44.4
2.9
2.6
1.7

balance-sheet.row.goodwill

0000
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0

balance-sheet.row.other-non-current-assets

2.281793.40.30.3
0
0.1
0.1

balance-sheet.row.total-non-current-assets

17.6731935.74.8
2.9
2.7
1.8

balance-sheet.row.other-assets

0000
0
0
0

balance-sheet.row.total-assets

77.298593.943.191
11.3
13.7
14.1

balance-sheet.row.account-payables

3.311336.32.41
2.8
1.2
0.9

balance-sheet.row.short-term-debt

1.768.80.60
19.1
0
0

balance-sheet.row.tax-payables

0000
0
0
0

balance-sheet.row.long-term-debt-total

0.6100.40
53.6
53.6
0

Deferred Revenue Non Current

0000
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-

balance-sheet.row.other-current-liab

19.333679.17.46.2
2.5
1.9
2.1

balance-sheet.row.total-non-current-liabilities

0.6100.40.1
0
0.1
0.3

balance-sheet.row.other-liabilities

0000
0
0
0

balance-sheet.row.capital-lease-obligations

2.3168.810
0
0
0

balance-sheet.row.total-liab

24.955084.210.87.3
27.1
3.1
3.3

balance-sheet.row.preferred-stock

00091032.1
53.6
53.6
35

balance-sheet.row.common-stock

0.012.600
0
0
0

balance-sheet.row.retained-earnings

-847.03-222594-190.2-127.7
-77.6
-47.7
-27.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0

balance-sheet.row.other-total-stockholders-equity

899.36226101.1222.5-90820.6
8.2
4.7
3

balance-sheet.row.total-stockholders-equity

52.343509.732.383.8
-15.8
10.6
10.8

balance-sheet.row.total-liabilities-and-stockholders-equity

77.298593.943.191
11.3
13.7
14.1

balance-sheet.row.minority-interest

0000
0
0
0

balance-sheet.row.total-equity

52.343509.732.383.8
-15.8
10.6
10.8

balance-sheet.row.total-liabilities-and-total-equity

77.29---
-
-
-

Total Investments

1.440051.5
0
1
11.6

balance-sheet.row.total-debt

2.3168.810
19.1
53.6
0

balance-sheet.row.net-debt

-48.49-3133.6-33.6-30.3
14.1
44.5
-0.4

Cash Flow Statement

The financial landscape of NexImmune, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -599.219. The company recently extended its share capital by issuing 0, marking a difference of 101357.055 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -44492000.000 in the reporting currency. This is a shift of -1.884 from the previous year. In the same period, the company recorded 1024.97, 4.23, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

cash-flows.row.net-income

-32.34-32344.4-62.5-50.9
-29.9
-20.5
-12.8

cash-flows.row.depreciation-and-amortization

1.02102510.9
0.6
0.4
0.2

cash-flows.row.deferred-income-tax

0.681041.10-3.3
0.4
0
0

cash-flows.row.stock-based-compensation

3.553553.65.96
1.2
1.5
1.2

cash-flows.row.change-in-working-capital

-4.88-1041.13.90.7
-0.1
-0.8
0.3

cash-flows.row.account-receivables

0000
0
0
0

cash-flows.row.inventory

0000
0
0
0

cash-flows.row.account-payables

-1.04-1041.11.4-1
0.7
0.2
0.2

cash-flows.row.other-working-capital

-3.841041.12.51.7
-0.8
-1.1
0.1

cash-flows.row.other-non-cash-items

0.54-2623.50.50.9
1.3
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-31.43000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.05-48.7-1.3-2.4
-0.9
-1.2
-0.9

cash-flows.row.acquisitions-net

000.1-32.1
0
0
0

cash-flows.row.purchases-of-investments

00-21.5-90.5
0
-7.1
-17.6

cash-flows.row.sales-maturities-of-investments

007339
1
17.7
5.9

cash-flows.row.other-investing-activites

04.2032.1
0.1
0
0

cash-flows.row.net-cash-used-for-investing-activites

-0.04-44.550.3-53.8
0.2
9.4
-12.6

cash-flows.row.debt-repayment

0000
0
0
0

cash-flows.row.common-stock-issued

005.1114.7
0
18.8
0

cash-flows.row.common-stock-repurchased

0000
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0

cash-flows.row.other-financing-activites

00010.2
22.1
0
9.2

cash-flows.row.net-cash-used-provided-by-financing-activities

005.2124.9
22.1
18.8
9.2

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0

cash-flows.row.net-change-in-cash

-31.47-31474.94.325.3
-4.1
8.8
-14.6

cash-flows.row.cash-at-end-of-period

50.983222.534.730.4
5.1
9.2
0.4

cash-flows.row.cash-at-beginning-of-period

82.4634697.330.45.1
9.2
0.4
15

cash-flows.row.operating-cash-flow

-31.43-31430.4-51.2-45.8
-26.4
-19.4
-11.1

cash-flows.row.capital-expenditure

-0.05-48.7-1.3-2.4
-0.9
-1.2
-0.9

cash-flows.row.free-cash-flow

-31.48-31479.1-52.4-48.1
-27.3
-20.7
-12.1

Income Statement Row

NexImmune, Inc.'s revenue saw a change of 0.000% compared with the previous period. The gross profit of NEXI is reported to be 0. The company's operating expenses are 32973.62, showing a change of 52170.311% from the last year. The expenses for depreciation and amortization are 1024.97, which is a 0.000% change from the last accounting period. Operating expenses are reported to be 32973.62, which shows a 52170.311% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -521.703% year-over-year growth. The operating income is -32973.62, which shows a 521.703% change when compared to the previous year. The change in the net income is -63.904%. The net income for the last year was -32344.39.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

income-statement-row.row.total-revenue

0000
0
0
0

income-statement-row.row.cost-of-revenue

1.0601.50.9
0.6
0.4
0

income-statement-row.row.gross-profit

-1.060-1.5-0.9
-0.6
-0.4
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0

income-statement-row.row.research-development

19.28---
-
-
-

income-statement-row.row.selling-general-administrative

13---
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-

income-statement-row.row.other-expenses

-0.07690.8-0.1-0.1
0.1
0.1
0.1

income-statement-row.row.operating-expenses

32.2832973.663.153.3
27.9
20.9
13.2

income-statement-row.row.cost-and-expenses

32.2832973.663.153.3
27.9
20.9
13.2

income-statement-row.row.interest-income

0.7698.40.70.1
0
0.2
0.3

income-statement-row.row.interest-expense

-260.330-576.70.9
1.7
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.33629.20.62.4
-2
0.3
0.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-

income-statement-row.row.other-operating-expenses

-0.07690.8-0.1-0.1
0.1
0.1
0.1

income-statement-row.row.total-operating-expenses

-0.33629.20.62.4
-2
0.3
0.1

income-statement-row.row.interest-expense

-260.330-576.70.9
1.7
0
0

income-statement-row.row.depreciation-and-amortization

1.0200.60.9
0.7
0.4
0.2

income-statement-row.row.ebitda-caps

-31.52---
-
-
-

income-statement-row.row.operating-income

-32.97-32973.6-63.1-53.3
-27.9
-20.9
-13.2

income-statement-row.row.income-before-tax

-32.34-32344.4-62.5-50.9
-29.9
-20.5
-12.8

income-statement-row.row.income-tax-expense

-260.870-576.70.8
1.8
-0.2
0.4

income-statement-row.row.net-income

227.99-32344.4514.2-51.7
-31.6
-20.3
-12.8

Frequently Asked Question

What is NexImmune, Inc. (NEXI) total assets?

NexImmune, Inc. (NEXI) total assets is 8593949000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.000.

What is company free cash flow?

The free cash flow is -882.647.

What is enterprise net profit margin?

The net profit margin is 0.000.

What is firm total revenue?

The total revenue is 0.000.

What is NexImmune, Inc. (NEXI) net profit (net income)?

The net profit (net income) is -32344393000.000.

What is firm total debt?

The total debt is 68809000.000.

What is operating expences number?

The operating expences are 32973622000.000.

What is company cash figure?

Enretprise cash is 3202452.000.